Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CX1440 capsules in adults with persistent or chronic primary immune thrombocytopenia
CTR20222290Phase 2Completed
- Sponsor
- Hangzhou Bangshun Pharmaceutical
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bangsaitinib in immune thrombocytopenia (ITP), sponsored by Hangzhou Bangshun Pharmaceutical. Started Feb 2023; status: completed.
02
Drugs
bangsaitinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20222290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222290.